Nanomedical Diagnostics Announces Company Name Change to Cardea to Encompass Internet of Biology Initiatives

Share Article

Cardea is committing to building the infrastructure of the Internet of Biology by providing its powerful graphene biosensor platform for OEM partnerships for anyone relevant. This includes next-gen pharmaceutical developers, rapid diagnostics companies, precision medicine providers and cutting-edge life science experts.

Michael Heltzen, new co-CEO of Cardea

This is the first time in history where the biological domain can be directly integrated with the digital domain, enabling faster time to actionable data, knowledge, results, insights, and decisions.

Nanomedical Diagnostics, the world’s leading manufacturer of high-quality graphene biosensors, hereby announces its corporate name change to Cardea, effective January 21, 2019.

The new name reflects a significant expansion of the company’s commercial activities, from primarily serving the pharmaceutical industry with ultra sensitive biosensor research tools, to opening its breakthrough biosensor platform for a broad set of healthcare and life science partners. Cardea has implemented a new business model that allows for OEM partnerships. This gives license partners access to the unique and powerful graphene biosensor infrastructure previously commercialized under the Nanomedical Diagnostics name.

“Our graphene biosensors have the ability to network biology with computers. This technology platform offers a feature the world has never seen before by presenting an immediate way of detecting what’s happening in the biology around you. For our Innovation Partners this translates into new market opportunities and competitive advantages, with the ability to build a new generation of products that allow for quick and easy biological insight. As we are the first to offer this kind of technology, we see it as our responsibility to make it available to the world,” said co-founder and co-CEO Ross Bundy. “We see the beginnings of an Internet of Biology, powered by Cardea biosensors, that lets biological information be accessed by everyone, instantly.”

To facilitate this ambitious expansion of business commitments, the company is also pleased to announce the addition of Michael Heltzen as co-CEO. Mr. Bundy states; “Michael has been a friend, investor and adviser since the beginning of the company, and our relationship has been both synergistic and productive. His passion for building commercial relationships, executing strategic implementation of technology visions, and his experience in protecting and leveraging intellectual property will be critical during this new phase of the company. I’m excited to bring Michael on board to help implement this expansion of the company’s goals.”

Mr. Heltzen echoes Mr. Bundy’s sentiments on the Internet of Biology and the company’s name change. “The name Cardea - the Roman goddess of hinges and therefore gates - underlines the pivotal and unique aspect of our proprietary graphene biosensor platform. We allow the biological molecules of interest to be the critical part of the electrical system that makes up our biosensors. This way we connect biology to the digital networks in a way the world has never seen before. This direct integration of biology and computing power gives us a live signal from the complex actions and interactions of the biology we normally think of as disease, health, drugs, food and more.”

“This is the first time in history where the biological domain can be directly integrated with the digital domain, enabling faster time to actionable data, knowledge, results, insights, and decisions—therefore real life impact. What we see here is the beginnings of the “Internet of Biology” that people have been only talking about up until now. We want to allow biological information to be accessible by everyone, like when we search the Internet for facts. We need to have the same immediate responses and insights also in life science and healthcare,” said Mr. Heltzen.

Current products and business activities under the Nanomedical Diagnostics brand umbrella will continue under the shortened name Nanomed as a Cardea brand. Cardea’s new OEM biosensor infrastructure and partnership business will be run under the Cardea name.

About Cardea

Cardea is the world’s leading manufacturer and developer of breakthrough digital graphene biosensors that among other things are being used to power the Internet of Biology. Cardea’s mission is to help transform the life science and healthcare industries with innovative new capabilities that enable Cardea partners to offer the world next-generation pharmaceutical development and monitoring, rapid onsite diagnostics, and cutting-edge life science applications.

About Nanomed

Nanomed is a Cardea brand used in the pharma and biotech industry. The Nanomed team strives to bring our biotech and pharmaceutical customers the most innovative and powerful biosensor research tools to accelerate drug discovery and development.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Michael Heltzen
Cardea
650.933.7700
Email >
Nanomedical Diagnostics
Like >
Visit website